ATLASATLAS fair value
ATLAS has no fair value for this stock today.
uniQure N.V. (QURE)
uniQure N.V. stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$24.28▲ +12.15%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on uniQure N.V. in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On uniQure N.V.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives uniQure N.V. a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $19.29 and $28.03; in 9 out of 10, between $13.85 and $39.04. Estimated annual volatility is 118%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $1.6B
- 52-week high
- $70.88
- 52-week low
- $8.73
- Revenue (12 months)
- $18.7M
- Revenue growth (YoY)
- -40.6%
- Gross margin
- 89.5%
- Return on equity
- -157.6%
- Free cash flow (12 months)
- $-77.6M
- Beta
- 1.06
What this means
ATLAS does not publish a fair value for QURE right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks QURE has traded between $8.73 and $70.88. Today it is 65.7% below that high and 178% above its low.
Its beta is 1.06: it moves roughly in line with the market.
About the company
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases.
Want to see everything about uniQure N.V.?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does uniQure N.V. do?
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases.
What is the chance QURE goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, QURE ends the month between $19.29 and $28.03.
How big is uniQure N.V. and what is its P/E ratio?
uniQure N.V.'s market capitalization is $1.6B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is QURE?
ATLAS estimates annual volatility at 118%. In a typical month, half of the outcomes end between $19.29 and $28.03.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer